38 - 1 (87) 2026 - Artykova M.A., Vakhobov S.G. - SOME ETIOPATHOGENETIC ASPECTS OF ALZHEIMER’S DISEASE

SOME ETIOPATHOGENETIC ASPECTS OF ALZHEIMER’S DISEASE

Artykova M.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Vakhobov S.G. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder. AD accounts for approximately 80% of dementia cases worldwide, particularly among elderly individuals over the age of 60. Symptoms associated with Alzheimer’s disease include severe memory impairment as well as progressive loss of motor and cognitive functions. A bidirectional interaction between the gut microbiota and the brain has been established, which plays a significant role in the development of neuropsychiatric disorders. The limited effectiveness of pharmacological agents in clinical trials has revealed substantial gaps in our understanding of the pathogenesis of AD. This necessitates a reconsideration of the etiology of Alzheimer’s disease from a novel perspective. This review highlights the importance of the gut microbiome in the etiology and pathogenesis of AD and discusses the potential role of probiotics in the therapy of Alzheimer’s disease.

Key words: Alzheimer’s disease, etiology and pathogenesis, gut microbiome, probiotics, treatment.

First page

215

Last page

218

For citation:Artykova M.A., Vakhobov S.G. - SOME ETIOPATHOGENETIC ASPECTS OF ALZHEIMER’S DISEASE//New Day in Medicine 1(87)2026 215-218 https://newdayworldmedicine.com/en/new_day_medicine/1-87-2026

List of References

  1. Ashford, M. T., Veitch, D. P., Neuhaus, J., Nosheny, R. L., Tosun, D., Weiner, M. W. (2021). The search for a convenient procedure to detect one of the earliest signs of Alzheimer’s disease: A systematic review of the prediction of brain amyloid status. Alzheimer’s Dementia, 2021;17(5):866-887. https://doi.org/10.1002/alz.12253
  2. Barrett, E., Ross, R. P., O’Toole, P. W., Fitzgerald, G. F., Stanton, C. (2012). γ-Aminobutyric acid production by culturable bacteria from the human intestine. Journal of Applied Microbiology, 2012;113(2):411-417. https://doi.org/10.1111/j.1365- 2672.2012.05344.x
  3. Glenner, G. G., Wong, C. W. (1984). Alzheimer’s disease and Down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research Communications, 1984;122(3):1131-1135. https://doi.org/10.1016/ 0006-291x(84)91209-9
  4. Go, J., Chang, D. H., Ryu, Y. K., Park, H. Y., Lee, I. B., Noh, J. R., et al. (2021). Human gut microbiota Agathobaculum butyriciproducens improves cognitive impairment in LPS-induced and APP/PS1 mouse models of Alzheimer’s disease. Nutrition Research, 2021;86:96-108. https://doi.org/10.1016/j.nutres.2020.12.010
  5. Holtzman D.M., Morris J.C., Goate A.M. (2011). Alzheimer#x2019; s Disease: The Challenge of the Second Century. Science Translational Medicine, 2011;3(77):7771-7771. doi:10.1126/scitranslmed.3002369.
  6. Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., et al. (2016). Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of Neurology, 2016;79(1):110–119. https://doi.org/10.1002/ana.24546
  7. Kandimalla, R., Reddy, P. H. (2017). Therapeutics of neurotransmitters in Alzheimer’s disease. Journal of Alzheimer’s Disease, 2017;57(4):1049-1069.
  8. Kesika P., Suganthy, N., Sivamaruthi, B.S., Chaiyasut C. (2021). Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease. Life Sciences, 264, Article 118627. https://doi.org/ 10.1016/j.lfs. 2020.118627
  9. Konijnenberg E., Tomassen J., den Braber A., ten Kate M., Yaqub M., Mulder S. D., et al. (2021). Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021;89(5):987-1000. https://doi.org/10.1002/ana.26048
  10. Mattsson-Carlgren N., Andersson E., Janelidze S., Ossenkoppele R., Insel P., Strandberg O., et al. (2020). Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’ s disease. Science. Advances, 6(16), eaaz2387. https://doi.org/ 10.1126/sciadv.aaz2387
  11. Pardo-Moreno, T., Gonz´alez-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., et al. (2022). Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives. Pharmaceutics, 2022;14(6):11-17.
  12. Singh R. P., Shadan A., Ma Y. (2022). Biotechnological Applications of Probiotics: A Multifarious Weapon to Disease and Metabolic Abnormality. Probiotics and Antimicrobial Proteins, 2022;14(6):1184–1210. https://doi.org/10.1007/s12602-022- 09992-8
  13. Shi, H., Wang, Q., Zheng, M., Hao, S., Lum, J. S., Chen, X., et al. (2020). Supplement of microbiota-accessible carbohydrates prevents neuroinflammation and cognitive decline by improving the gut microbiota-brain axis in diet-induced obese mice. Journal of neuroinflammation, 2020;17(1):1-21.
  14. Xiao J., Katsumata, N., Bernier, F., Ohno, K., Yamauchi, Y., Odamaki, T., et al. (2020). Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer’s Disease, 2020;77(1):139–147. https://doi.org/ 10.3233/jad-200488
  15. Ye H., Han Y., Li P., Su, Z., Huang, Y. (2022). The Role of Post-Translational Modifications on the Structure and Function of Tau Protein. Journal of Molecular Neuroscience, 2022;72(8):1557-1571. https://doi.org/10.1007/s12031-022-02002-0

    file

    download